The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis.
 
Grainne M. O'Kane
Honoraria - AstraZeneca; Eisai; MSD Oncology; Roche
Consulting or Advisory Role - AstraZeneca Canada; Eisai; Incyte; Roche; Servier
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Jennifer L. Spratlin
Honoraria - Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Pharmaceutical
Research Funding - Celgene (Inst); Sanofi
Travel, Accommodations, Expenses - Astellas Pharma
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Sun Young Rha
No Relationships to Disclose
 
Elena Elimova
Employment - Merck (I)
Consulting or Advisory Role - Adaptimmune (Inst); Astellas Pharma; BeiGene (Inst); Bristol-Myers Squibb (Inst); Viracta Therapeutics; Zymeworks (Inst)
Research Funding - AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst)
 
Petr Kavan
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer; Roche Canada; Taiho Oncology
 
Moon Ki Choi
No Relationships to Disclose
 
Rachel Anne Goodwin
Honoraria - Advanced Accelerator Applications; Eisai; Incyte; Incyte; Ipsen; Merck; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Amgen; Apobiologix; Astellas Pharma; AstraZeneca Canada; Bayer; Eisai; Incyte; Ipsen; Merck; MSD; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical; Viatris
Speakers' Bureau - Amgen; Bayer; Bayer; Eisai; Ipsen; Merck; Mylan; Pfizer
Research Funding - Eisai; Ipsen
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer
 
Seung Tae Kim
No Relationships to Disclose
 
Dong-Hoe Koo
No Relationships to Disclose
 
Khalif Halani
No Relationships to Disclose
 
E Russell McAllister
Employment - Bold Therapeutics
Leadership - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
Patents, Royalties, Other Intellectual Property - Bold Therapeutics
Travel, Accommodations, Expenses - Bold Therapeutics
 
Michelle Jones
Employment - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
 
Malcolm Snow
Employment - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
 
Yasmin Lemmerick
No Relationships to Disclose
 
Gonzalo Spera
No Relationships to Disclose
 
Jim Pankovich
Employment - Bold Therapeutics
Leadership - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
Patents, Royalties, Other Intellectual Property - Bold Therapeutics Inc. patents